ESC 2024 - “We did not demonstrate that it was safe to stop or withdrawal β-blocker in post-MI patients, even if they were stabilized with preserved ejection fraction”, says Johanne Silvain in response to the ABYSS study findings.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - “We did not demonstrate that it was safe to stop or withdrawal β-blocker in post-MI patients, even if they were stabilized with preserved ejection fraction”, says Johanne Silvain in response to the ABYSS study findings.
This video was recorded during the ESC Congress 2024 in London, UK.
Johanne Silvain, MD, PhD is a Professor of Cardiology at the Sorbonne University and an Interventional Cardiologist at the Institut de Cardiologie at the Pitié-Salpêtrière Hospital in Paris, France.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 30 August 2024
ESC 2024 - “We did not demonstrate that it was safe to stop or withdrawal β-blocker in post-MI patients, even if they were stabilized with preserved ejection fraction”, says Johanne Silvain in response to the ABYSS study findings.
This video was recorded during the ESC Congress 2024 in London, UK.
Johanne Silvain, MD, PhD is a Professor of Cardiology at the Sorbonne University and an Interventional Cardiologist at the Institut de Cardiologie at the Pitié-Salpêtrière Hospital in Paris, France.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 30 August 2024
Stay current with the best on medical education
